Patents Assigned to Everist Genomics, Inc.
  • System and method for using flow-mediated dilation to provide an adjusted vascular age as an indicator of risk of cardiovascular disease
    Patent number: 10568582
    Abstract: A diagnostic tool 104 and method 300 are used to modify vascular age scoring systems using flow-mediated dilation (FMD) data. The resulting FMD-adjusted vascular age calculator can be used to diagnose a person's potential for developing cardiovascular disease.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 25, 2020
    Assignee: Everist Genomics, Inc.
    Inventors: Peter F. Lenehan, Thomas Stephen Everist, III
  • System and method of assessing endothelial function
    Patent number: 10485429
    Abstract: A medical diagnostic system and method for assessing endothelial function comprise adjusting a reactive hyperemia indicator, measured in response to a stimulus, based on an anthropomorphic and/or demographic variable. The adjusted reactive hyperemia indicator provides a more accurate reflection of endothelial function and can be communicated to a clinician.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: November 26, 2019
    Assignee: Everist Genomics, Inc.
    Inventors: Peter F. Lenehan, Thomas Stephen Everist, III
  • Method for non-evasively determining an endothelial function and a device for carrying out said method
    Patent number: 10238306
    Abstract: The invention relates to medicine. The inventive method for non-evasively determining an endothelial function consists in reducing a transmural pressure in a limb, recording the amplitude of plethysmographic signals at different pressures, determining the pressure of a maximum plethysmographic signal amplitude, reducing the pressure to a value corresponding to the specified percentage of the maximum amplitude, carrying out an occlusion sample in the course of which a pressure higher by at least 50 mm Hg than the systolic pressure of a tested patient is produced in a cuff arranged proximally to the located limb area, wherein the occlusion is carried out during at least 5 minutes.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: March 26, 2019
    Assignee: Everist Genomics, Inc.
    Inventors: Alexander Sergeevich Parfyonov, Maria Alexandrovna Parfyonova
  • Prognostic signature for colorectal cancer recurrence
    Patent number: 9234245
    Abstract: An assay system is useful for predicting recurrence and/or non-recurrence of colorectal cancer in a patient. The assay system is adapted to analyze a patient sample for quantitative expression of a prognostic genetic profile correlated with colorectal cancer recurrence. The profile includes the expression of the nucleic acid sequences of SEQ ID NOS: 1, 2, 3, 4, and 5.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: January 12, 2016
    Assignee: Everist Genomics, Inc.
    Inventors: William P. Worzel, Peter F. Lenehan, Arpit Almal, David W. Fry
  • Prognostic Signature for Colorectal Cancer Recurrance
    Publication number: 20120185174
    Abstract: An assay system is useful for predicting recurrence and/or non-recurrence of colorectal cancer in a patient. The assay system is adapted to analyze a patient sample for quantitative expression of a prognostic genetic profile correlated with colorectal cancer recurrence. The profile includes the expression of the nucleic acid sequences of SEQ ID NOS: 1, 2, 3, 4, and 5.
    Type: Application
    Filed: January 17, 2012
    Publication date: July 19, 2012
    Applicant: Everist Genomics, Inc.
    Inventors: William P. Worzel, Peter F. Lenehan, Arpit Almal, David W. Fry